• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab.

作者信息

Tong Zequn, Zhang Yihua, Zhou Kunli, Zou Ying, Wu Zhenlan, Chen Jiawen, Zhuang Zheyu, Zhao Yifan, Gong Ting, Ji Chao

机构信息

Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.

Department of Dermatology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.

出版信息

J Am Acad Dermatol. 2023 Oct;89(4):826-828. doi: 10.1016/j.jaad.2023.05.077. Epub 2023 Jun 10.

DOI:10.1016/j.jaad.2023.05.077
PMID:37307992
Abstract
摘要

相似文献

1
An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab.一项关于从度普利尤单抗转换治疗后使用阿布昔替尼治疗中度至重度特应性皮炎成人患者的观察性研究。
J Am Acad Dermatol. 2023 Oct;89(4):826-828. doi: 10.1016/j.jaad.2023.05.077. Epub 2023 Jun 10.
2
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).阿柏西普治疗成人中重度特应性皮炎的 3 期疗效和安全性：来自度普利尤单抗（JADE EXTEND）转换治疗的研究结果。
J Am Acad Dermatol. 2022 Aug;87(2):351-358. doi: 10.1016/j.jaad.2022.04.009. Epub 2022 Apr 16.
3
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.阿柏西普与度普利尤单抗治疗中重度特应性皮炎成人患者的疗效和安全性：一项随机、双盲、多中心 3 期临床试验。
Lancet. 2022 Jul 23;400(10348):273-282. doi: 10.1016/S0140-6736(22)01199-0.
4
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.阿泊替尼对比安慰剂或度普利尤单抗治疗特应性皮炎。
N Engl J Med. 2021 Mar 25;384(12):1101-1112. doi: 10.1056/NEJMoa2019380.
5
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.比较阿布昔替尼和度普利尤单抗治疗特应性皮炎：通俗易懂的总结。
Immunotherapy. 2022 Jan;14(1):5-14. doi: 10.2217/imt-2021-0224. Epub 2021 Nov 15.
6
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
7
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.阿泊替尼治疗早期瘙痒反应与中重度特应性皮炎患者的后期疗效结局相关：随机 III 期 JADE COMPARE 试验的亚组分析。
Am J Clin Dermatol. 2023 Jan;24(1):97-107. doi: 10.1007/s40257-022-00738-4. Epub 2022 Dec 13.
8
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.阿布昔替尼治疗成人和青少年中重度特应性皮炎的疗效和安全性（JADE MONO-1）：一项多中心、双盲、随机、安慰剂对照、3 期临床试验。
Lancet. 2020 Jul 25;396(10246):255-266. doi: 10.1016/S0140-6736(20)30732-7.
9
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.阿泊替尼治疗重度和/或难治性特应性皮炎患者的疗效和安全性：随机 3 期 JADE COMPARE 试验的事后分析。
Am J Clin Dermatol. 2023 Jul;24(4):609-621. doi: 10.1007/s40257-023-00785-5. Epub 2023 May 22.
10
Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis.JADE COMPARE 随机 3 期研究中阿泊替尼治疗中重度特应性皮炎成人患者的患者报告结局。
J Eur Acad Dermatol Venereol. 2022 Mar;36(3):434-443. doi: 10.1111/jdv.17813. Epub 2021 Dec 13.

引用本文的文献

1
Effectiveness and safety of age-based dosing of abrocitinib in children and adolescents with moderate to severe atopic dermatitis: A two-center, prospective real-world study in China.阿巴西普按年龄给药治疗中重度特应性皮炎儿童及青少年的有效性和安全性：一项在中国开展的两中心前瞻性真实世界研究。
Medicine (Baltimore). 2025 Apr 18;104(16):e42231. doi: 10.1097/MD.0000000000042231.
2
Comparative Analysis of the Efficacy of Abrocitinib and Dupilumab in the Treatment of Atopic Dermatitis.阿布昔替尼与度普利尤单抗治疗特应性皮炎的疗效对比分析
Clin Cosmet Investig Dermatol. 2025 Apr 6;18:817-825. doi: 10.2147/CCID.S515200. eCollection 2025.
3
Effects of abrocitinib on pruritus and eczema symptoms and tolerance in patients with moderate‑to‑severe atopic dermatitis in randomized, double‑blind and placebo‑controlled trials: A systematic review and a meta‑analysis.
在随机、双盲和安慰剂对照试验中，阿布昔替尼对中重度特应性皮炎患者瘙痒、湿疹症状及耐受性的影响：一项系统评价和荟萃分析
Biomed Rep. 2024 Mar 29;20(5):84. doi: 10.3892/br.2024.1772. eCollection 2024 May.
4
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.阿泊替尼治疗特应性皮炎和手部湿疹患者的真实世界经验：来自 BioDay 注册研究的长达 28 周的结果。
Acta Derm Venereol. 2024 Feb 7;104:adv19454. doi: 10.2340/actadv.v104.19454.